v3.26.1
SUBSEQUENT EVENTS (Details Narrative) - USD ($)
6 Months Ended
Aug. 05, 2026
Jul. 01, 2026
Nov. 13, 2025
Jun. 30, 2025
Mar. 31, 2025
Sep. 30, 2023
Subsequent Event [Line Items]            
Warrants to purchase common shares     880,000   630,376 73,474
Common Stock [Member]            
Subsequent Event [Line Items]            
Shares of common stock issuable       239,594    
Series B Preferred Stock [Member]            
Subsequent Event [Line Items]            
Converted shares of common stock     665,922      
Shares of common stock issuable     1,513      
Subsequent Event [Member] | 3i LP Agreement [Member]            
Subsequent Event [Line Items]            
Payment for cash $ 250,000          
Subsequent Event [Member] | Galephar Agreement [Member] | Common Stock [Member]            
Subsequent Event [Line Items]            
Shares of common stock issuable   2,170,767        
Subsequent Event [Member] | Series B Preferred Stock [Member] | 3i LP Agreement [Member] | Common Stock [Member]            
Subsequent Event [Line Items]            
Converted shares of common stock 3,229,276          
Subsequent Event [Member] | Series C Preferred Stock [Member] | 3i LP Agreement [Member] | Common Stock [Member]            
Subsequent Event [Line Items]            
Converted shares of common stock 1,000          
Warrants to purchase common shares 7,183          
Subsequent Event [Member] | Series C Preferred Stock [Member] | Galephar Agreement [Member] | Common Stock [Member]            
Subsequent Event [Line Items]            
Converted shares of common stock   1,000        
Shares of common stock issuable   2,171        
Cy Biopharma Inc [Member] | Subsequent Event [Member]            
Subsequent Event [Line Items]            
Private placement financing for gross proceeds $ 21,500,000          
Additional financing tranche $ 38,600,000